SG11202003486UA - Combination product for the treatment of cancer - Google Patents

Combination product for the treatment of cancer

Info

Publication number
SG11202003486UA
SG11202003486UA SG11202003486UA SG11202003486UA SG11202003486UA SG 11202003486U A SG11202003486U A SG 11202003486UA SG 11202003486U A SG11202003486U A SG 11202003486UA SG 11202003486U A SG11202003486U A SG 11202003486UA SG 11202003486U A SG11202003486U A SG 11202003486UA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
combination product
combination
product
Prior art date
Application number
SG11202003486UA
Inventor
Grégoire Vuagniaux
Norbert Wiedemann
Claudio Zanna
Original Assignee
Debiopharm Int Sa
Merck Patent Gmbh
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa, Merck Patent Gmbh, Pfizer filed Critical Debiopharm Int Sa
Publication of SG11202003486UA publication Critical patent/SG11202003486UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202003486UA 2017-10-19 2018-10-19 Combination product for the treatment of cancer SG11202003486UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574384P 2017-10-19 2017-10-19
EP18191980 2018-08-31
PCT/EP2018/078763 WO2019077132A1 (en) 2017-10-19 2018-10-19 Combination product for the treatment of cancer

Publications (1)

Publication Number Publication Date
SG11202003486UA true SG11202003486UA (en) 2020-05-28

Family

ID=63915057

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003486UA SG11202003486UA (en) 2017-10-19 2018-10-19 Combination product for the treatment of cancer

Country Status (12)

Country Link
US (2) US20210198365A1 (en)
EP (1) EP3697816A1 (en)
JP (2) JP7422070B2 (en)
KR (1) KR20200072507A (en)
CN (1) CN111655725A (en)
AU (1) AU2018353432A1 (en)
BR (1) BR112020007046A2 (en)
CA (1) CA3078155A1 (en)
IL (1) IL273835A (en)
MX (1) MX2020004074A (en)
SG (1) SG11202003486UA (en)
WO (1) WO2019077132A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3911316A1 (en) 2019-01-17 2021-11-24 Debiopharm International SA Combination product for the treatment of cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP3771253B2 (en) 1988-09-02 2006-04-26 ダイアックス コープ． Generation and selection of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS.
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
ATE452207T1 (en) 1992-08-21 2010-01-15 Univ Bruxelles IMMUNOGLOBULINS WITHOUT LIGHT CHAINS
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
EA017797B1 (en) 2007-04-13 2013-03-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Diazo bicyclic smac mimetics, processes for preparing, uses thereof, pharmaceutical compositions containing them and a kit comprising said compositions
CN108484767B (en) 2008-09-26 2022-01-14 达纳-法伯癌症研究公司 Human anti-PD-1, PD-L1 and PD-L2 antibodies and uses thereof
PE20120341A1 (en) 2008-12-09 2012-04-24 Genentech Inc ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE
KR101934071B1 (en) 2009-11-24 2019-01-02 메디뮨 리미티드 Targeted binding agents against b7-h1
ES2708669T3 (en) 2011-08-01 2019-04-10 Hoffmann La Roche Cancer treatment procedures using PD-1 axis-binding antagonists and MEK inhibitors
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
CA2926856A1 (en) 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
KR20170066546A (en) 2014-10-03 2017-06-14 노파르티스 아게 Combination therapies
EA201891904A1 (en) 2016-02-24 2019-04-30 Чилдрен'С Хоспитал Оф Истерн Онтарио Рисерч Инститьют Инк. SMC COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT NUMER FORMATION
JP2020515600A (en) * 2017-03-31 2020-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-cancer combination therapy

Also Published As

Publication number Publication date
US20240010731A1 (en) 2024-01-11
EP3697816A1 (en) 2020-08-26
US20210198365A1 (en) 2021-07-01
BR112020007046A2 (en) 2020-11-17
KR20200072507A (en) 2020-06-22
CA3078155A1 (en) 2019-04-25
JP2021500320A (en) 2021-01-07
CN111655725A (en) 2020-09-11
IL273835A (en) 2020-05-31
MX2020004074A (en) 2020-10-16
JP2024054123A (en) 2024-04-16
WO2019077132A1 (en) 2019-04-25
AU2018353432A1 (en) 2020-04-23
JP7422070B2 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
HK1247202A1 (en) Compounds for the treatment of cancer
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
HK1247129A1 (en) Combination therapy for the treatment of cancer
HK1251475A1 (en) Combination therapy for the treatment of cancer
IL267795A (en) Combination therapy for the treatment of cancer
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
IL259996A (en) Combinations for the treatment of cancer
PT3576740T (en) Cancer treatment
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
GB201706451D0 (en) Cancer treatment
IL275525A (en) Pharmaceutical composition for the treatment of cancer
IL268463A (en) Cancer treatment
IL266993A (en) Combination therapy for the treatment of cancer
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
IL274626A (en) Cancer treatment
IL273835A (en) Combination product for the treatment of cancer
GB201707864D0 (en) Platinum-reistant cancer treatment
PL3630754T3 (en) Isoindoline-acetylene compounds for the treatment of cancer
IL253642A0 (en) Combination therapy for the treatment of cancer
GB201713936D0 (en) Pharmaceutical combinations for the treatment of cancer
PT3580211T (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
GB201719584D0 (en) Pharmaceutical compositions for the treatment of cancer
GB201713852D0 (en) Cancer treatment
GB201704287D0 (en) Treatment of cancer
GB201703857D0 (en) Treatment of cancer